New immunotherapy plus chemo for resectable lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This Phase 3 trial studies whether an immunotherapy drug (SHR-1316) added to standard chemotherapy helps people live longer or delay cancer returning after surgery. It focuses on people with resectable non-small cell lung cancer (NSCLC) that has not been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have resectable stage II, IIIA, or selected IIIB NSCLC that was just diagnosed and confirmed by pathology
- Your cancer team believes you can likely have a complete (R0) surgery cure
- You have not had any prior anti-cancer treatment for lung cancer
- You must have measurable cancer on scans (meets RECIST v1.1 measurement rules)
- Your general health is good (ECOG 0 or 1) and your organs (heart, liver, kidneys, blood) function adequately
- You can provide enough tumor tissue for PD-L1 testing, and you use reliable birth control (or cannot get pregnant)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests a new drug, SHR-A2102, combined with other treatments for people with non-small cell lung cancer that can be removed with surgery. It aims to improve outcomes by using multiple therapies together.
This trial tests a new drug combined with other treatments for people with lung cancer that can be removed by surgery. It aims to see if the treatment shrinks tumors before surgery and improves outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
This trial tests whether combining an immunotherapy drug (adebrelimab or retlirafusp alfa) with another drug (recaticimab) and chemotherapy helps shrink lung cancer before surgery. The goal is to see if this approach improves outcomes for people with resectable non-small cell lung cancer.
This trial tests whether giving a type of immunotherapy (sintilimab) along with chemotherapy before and after surgery to remove the main lung tumor can help people with advanced non-small cell lung cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.